NR1H4 and metabolic dysfunction-associated steatohepatitis: In addition, the selective FXR agonist cilofexor (previously known as GS-9674) has been demonstrated to reduce hepatic steatosis in NASH patients and to have a good safety profile, indicating its potential treatment value in the control of NASH (Patel et al., 2020).